CN1481805A - Medication for hepatitis and its preparation method - Google Patents
Medication for hepatitis and its preparation method Download PDFInfo
- Publication number
- CN1481805A CN1481805A CNA031416586A CN03141658A CN1481805A CN 1481805 A CN1481805 A CN 1481805A CN A031416586 A CNA031416586 A CN A031416586A CN 03141658 A CN03141658 A CN 03141658A CN 1481805 A CN1481805 A CN 1481805A
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- gram
- medicine
- polyvidone
- baicalin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The medicine for treating hepatitis has astragaloside as active matter, stuffing avicel, disintegrating agent carboxymethylstarch sodium, lubricant talcum powder, adhesive PVPK30 and other supplementary material, and is prepared through certain technological process. The medicine of the present invention can clear away heat, drying wetness, promote blood circulation, eliminate toxic matter, invigorate kidney and spleen, regulate body's function, eliminate hepatitis virus, purify blood, improve liver's blood circulation, protect liver cell, restore liver's function and cure hepatitis radically. The present invention as one novel hepatitis treating medicine has the advantages of determined curative effect, no side effect, no recurrence, etc.
Description
Technical field
What the present invention relates to is medicine in the field of medicaments, and especially relating to a kind of is the medicine and preparation method thereof of the treatment hepatitis of active substance with the baicalin.
Technical background
Hepatitis is a kind of infectious disease, divide first, second, third, fourth, penta,, 7 kinds of heptan, because it is popular extensively, hazardness is big, sickness rate is high, being one of difficult and complicated illness of generally acknowledging both at home and abroad at present, is example with the hepatitis B, and just there is hepatitis B patient nearly 50,000,000 in light China, annual newly-increased patient about 1,100,000, cure rate is 10% only, and the overwhelming majority transfers chronic hepatitis to, serious hepatic ascites, the hepatocarcinoma of being converted into.The drug variety for the treatment of hepatitis at present clinically is very many, but most of curative effect is not obvious, and some medicine also has significant side effects, and the harm people's is healthy.
Summary of the invention
The purpose of this invention is to provide medicine of a kind of treatment hepatitis that is active substance, determined curative effect with the baicalin, has no side effect and preparation method thereof.
The object of the present invention is achieved like this: prescription of the present invention is made up of following raw materials according, and its composition is counted with per 1000 contained weight:
Baicalin: 200-300 gram
Microcrystalline Cellulose: 15-30 gram
Carboxymethylstach sodium: 25-35 gram
Pulvis Talci: 1-3 gram
Polyvidone
K30: the 4-8 gram.
Preparation method of the present invention is:
(1), baicalin, microcrystalline Cellulose, carboxymethylstach sodium, Pulvis Talci are crossed 80 mesh sieves respectively;
(2), with polyvidone
K30Become 4% solution with 50% dissolve with ethanol, mix homogeneously obtains polyvidone
K30Liquid;
(3), baicalin, microcrystalline Cellulose, carboxymethylstach sodium mix homogeneously after will sieving, obtain mixture;
(4), with 4% polyvidone
K30Liquid is poured in the mixture and is stirred, and mixes kneading and becomes soft material, crosses 20 mesh sieves, the wet grain of system;
(5), the grain that will wet is dry under 60 ℃ of environment, reuse 18 mesh sieve granulate add Pulvis Talci then, mix homogeneously is made capsule and is got product.
Baicalin is to extract and get from the Radix Scutellariae root, and Radix Scutellariae is a labiate, and bitter in the mouth is cold in nature, has effects such as heat clearing and damp drying, eliminating fire and detoxication.Baicalin has and removes the function damp and hot, that removing the relative excess is fiery, can be used for acute, delay property, chronic hepatitis.
The present invention is to be active substance with the baicalin, and is aided with filler: microcrystalline Cellulose, disintegrating agent: carboxymethylstach sodium, lubricant: Pulvis Talci, binding agent: polyvidone
K30(PVP
K30) wait adjuvant, adopt certain prepared to form.Medicine of the present invention can heat clearing and damp drying, the toxin expelling of invigorating blood circulation, kidney and spleen invigorating, effectively adjust that various functions participate in killing and eliminating hepatitis virus in the body; purify the blood and improve liver blood circulation, protection hepatocyte, recovery liver function; fundamentally cure hepatitis; the present invention also has determined curative effect, has no side effect, the advantage of non-relapse after healing, nothing knock-on, is a kind of medicine of novel therapeutic hepatitis.
The specific embodiment
Be described in further detail the present invention below in conjunction with embodiment, but should understand the scope that scope of the present invention is not limited only to these embodiment.
Embodiment 1
1, baicalin, microcrystalline Cellulose, carboxymethylstach sodium, Pulvis Talci are crossed 80 mesh sieves respectively, take by weighing baicalin 200 grams, microcrystalline Cellulose 15 grams, carboxymethylstach sodium 25 grams, Pulvis Talci 1 gram after sieving then respectively, standby;
2, take by weighing 4 gram povidone iodine, povidone iodine is become 4% solution with 50% dissolve with ethanol, mix homogeneously obtains povidone iodine;
3, with baicalin, microcrystalline Cellulose, carboxymethylstach sodium mix homogeneously, obtain mixture;
4, with 4% polyvidone
K30Liquid is poured in the mixture and is stirred, and mixes kneading and becomes soft material, crosses 20 mesh sieves, the wet grain of system;
5, the grain that will wet is dry under 60 ℃ of environment, and reuse 18 mesh sieve granulate add Pulvis Talci then, and mix homogeneously is made 1000 capsules and got product.
Embodiment 2
1, baicalin, microcrystalline Cellulose, carboxymethylstach sodium, Pulvis Talci are crossed 80 mesh sieves respectively, take by weighing baicalin 300 grams, microcrystalline Cellulose 30 grams, carboxymethylstach sodium 35 grams, Pulvis Talci 3 grams after sieving then respectively, standby;
2, take by weighing 8 gram polyvidones
K30, with polyvidone
K30Become 4% solution with 50% dissolve with ethanol, mix homogeneously obtains polyvidone
K30Liquid;
3, with baicalin, microcrystalline Cellulose, carboxymethylstach sodium mix homogeneously, obtain mixture;
4, with 4% polyvidone
K30Liquid is poured in the mixture and is stirred, and mixes kneading and becomes soft material, crosses 20 mesh sieves, the wet grain of system;
5, the grain that will wet is dry under 60 ℃ of environment, and reuse 18 mesh sieve granulate add Pulvis Talci then, and mix homogeneously is made 1000 capsules capsules and got product.
Embodiment 3
1, baicalin, microcrystalline Cellulose, carboxymethylstach sodium, Pulvis Talci are crossed 80 mesh sieves respectively, take by weighing baicalin 250 grams, microcrystalline Cellulose 25 grams, carboxymethylstach sodium 28 grams, Pulvis Talci 2 grams after sieving then respectively, standby;
2, take by weighing 6 gram polyvidones
K30, with polyvidone
K30Become 4% solution with 50% dissolve with ethanol, mix homogeneously obtains polyvidone
K30Liquid;
3, with baicalin, microcrystalline Cellulose, carboxymethylstach sodium mix homogeneously, obtain mixture;
4, with 4% polyvidone
K30Liquid is poured in the mixture and is stirred, and mixes kneading and becomes soft material, crosses 20 mesh sieves, the wet grain of system;
5, the grain that will wet is dry under 60 ℃ of environment, and reuse 18 mesh sieve granulate add Pulvis Talci then, and mix homogeneously is made 1000 capsules capsules and got product.
Claims (2)
1, a kind of medicine for the treatment of hepatitis is characterized in that: prescription is made up of following raw materials according, and its composition is counted with per 1000 contained weight:
Baicalin: 200-300 gram
Microcrystalline Cellulose: 15-30 gram
Carboxymethylstach sodium: 25-35 gram
Pulvis Talci: 1-3 gram
Polyvidone
K30: the 4-8 gram.
2. the preparation method of the medicine of treatment hepatitis as claimed in claim 1 is characterized in that:
(1), baicalin, microcrystalline Cellulose, carboxymethylstach sodium, Pulvis Talci are crossed 80 mesh sieves respectively;
(2), with polyvidone
K30Become 4% solution with 50% dissolve with ethanol, mix homogeneously obtains polyvidone
K30Liquid;
(3), baicalin, microcrystalline Cellulose, carboxymethylstach sodium mix homogeneously after will sieving, obtain mixture;
(4), with 4% polyvidone
K30Liquid is poured in the mixture and is stirred, and mixes kneading and becomes soft material, crosses 20 mesh sieves, the wet grain of system;
(5), the grain that will wet is dry under 60 ℃ of environment, reuse 18 mesh sieve granulate add Pulvis Talci then, mix homogeneously is made capsule and is got product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031416586A CN1481805A (en) | 2003-07-14 | 2003-07-14 | Medication for hepatitis and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031416586A CN1481805A (en) | 2003-07-14 | 2003-07-14 | Medication for hepatitis and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1481805A true CN1481805A (en) | 2004-03-17 |
Family
ID=34155390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031416586A Pending CN1481805A (en) | 2003-07-14 | 2003-07-14 | Medication for hepatitis and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1481805A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1330312C (en) * | 2005-06-27 | 2007-08-08 | 宛六一 | Baicalin soft capsule and preparation method thereof |
| GB2455151A (en) * | 2007-11-27 | 2009-06-03 | Phynova Ltd | An Astragalus extract as an antiviral for several genera of the Flaviviridae family |
| CN1981779B (en) * | 2005-12-05 | 2010-05-19 | 山东轩竹医药科技有限公司 | Xanthosine composition and its production method |
| CN102091085A (en) * | 2011-01-11 | 2011-06-15 | 中山大学 | Compound pharmaceutical composition for improving oral bioavailability of taxol and application thereof |
| US8197860B2 (en) * | 2005-06-23 | 2012-06-12 | Nuliv Holding Inc. | Method for enhancing nutrient absorption with astragalosides |
| CN101744830B (en) * | 2008-06-17 | 2012-09-05 | 上海医药工业研究院 | Flavonoid compound and application of plant extract containing same |
| CN109288854A (en) * | 2018-11-27 | 2019-02-01 | 东莞市金美济药业有限公司 | A kind of secretion in HepG 2.2.2.15, baicalin capsules and preparation method thereof |
-
2003
- 2003-07-14 CN CNA031416586A patent/CN1481805A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8197860B2 (en) * | 2005-06-23 | 2012-06-12 | Nuliv Holding Inc. | Method for enhancing nutrient absorption with astragalosides |
| CN1330312C (en) * | 2005-06-27 | 2007-08-08 | 宛六一 | Baicalin soft capsule and preparation method thereof |
| CN1981779B (en) * | 2005-12-05 | 2010-05-19 | 山东轩竹医药科技有限公司 | Xanthosine composition and its production method |
| GB2455151A (en) * | 2007-11-27 | 2009-06-03 | Phynova Ltd | An Astragalus extract as an antiviral for several genera of the Flaviviridae family |
| CN101744830B (en) * | 2008-06-17 | 2012-09-05 | 上海医药工业研究院 | Flavonoid compound and application of plant extract containing same |
| CN102091085A (en) * | 2011-01-11 | 2011-06-15 | 中山大学 | Compound pharmaceutical composition for improving oral bioavailability of taxol and application thereof |
| CN109288854A (en) * | 2018-11-27 | 2019-02-01 | 东莞市金美济药业有限公司 | A kind of secretion in HepG 2.2.2.15, baicalin capsules and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1481805A (en) | Medication for hepatitis and its preparation method | |
| CN1709451A (en) | Underleaf pearl formulation for treatig liver-gallbladder diseases and its preparing method | |
| CN1730048A (en) | Chinese medicinal composition for treating piles and anal fissure and process for preparing the same | |
| CN101032612A (en) | Medicine preparation for curing inflammation and tumour and its prepn process | |
| CN100335119C (en) | Chinese medicinal composition for treating enteritis | |
| CN102961511A (en) | Medicine for treating paronychia and preparation method for same | |
| CN1051468C (en) | Capsule for curing rheumatism | |
| CN1857482A (en) | Compound Chinese medicine preparation for clearing away heat, drying damp, disinsecting and stopping itch and its preparing process | |
| CN1085542C (en) | Oral preparation of traditional Chinese medicine medicated composition for treating psoriasis and its preparation method | |
| CN103405647A (en) | TCM composition for treating nephritis and kidney failure | |
| CN112891482B (en) | A composition for treating coronavirus infection | |
| CN1430981A (en) | Zedoary oil product of virus safe medicine and its preparing method | |
| CN1277559C (en) | Medicine for treating rheumatism and its preparation | |
| CN1201769C (en) | Medicine for treating diabetes, nephropathy | |
| CN107669738B (en) | Traditional Chinese medicine preparation for promoting blood circulation to remove blood stasis, tonifying qi and strengthening heart and preparation method thereof | |
| WO2018006643A1 (en) | Traditional chinese medicine for providing man with kidney-tonifying, blood circulation-promoting and liver-soothing benefits | |
| CN1923230A (en) | Medicine for treating rheumatism and rheumatoid disease, and its preparation method | |
| CN1823761A (en) | Yiganling dispersion tablet for treating liver disease and its preparation method | |
| CN100350943C (en) | Medicinal composition for treating hepatitis B and preparation method thereof | |
| CN1857544A (en) | Chinese medicine preparation for treating hyperosteogeny | |
| CN1692916A (en) | Pharmaceutical prepn. of compound mannite, and its prepn. method | |
| CN1515305A (en) | Compound powder peparation for curing gynecopathy, its preparation method and application | |
| CN1247217C (en) | Chinese medicine preparation for treating lithiasis of urinary system, and preparing method thereof | |
| CN1559503A (en) | Mango couth suppressing capsule and method of preparatuion long effect capsule | |
| CN1292765C (en) | Pharmaceutical composition, its preparation process and usage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |